Ironwood Pharmaceuticals, Inc. (IRWD) DCF Valuation

Ironwood Pharmaceuticals, Inc. (IRWD) Évaluation DCF

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
Ironwood Pharmaceuticals, Inc. (IRWD) DCF Valuation
  • Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • Aucune Expertise N'Est Requise; Facile À Suivre

Ironwood Pharmaceuticals, Inc. (IRWD) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Découvrez le véritable potentiel d'Ironwood Pharmaceuticals, Inc. (IRWD) avec notre calculatrice avancée DCF! Personnalisez les hypothèses clés, explorez divers scénarios et évaluez comment les différents changements affectent l'évaluation Ironwood Pharmaceuticals, Inc. (IRWD) - le tout dans un modèle Excel convivial.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019
AY2
2020
AY3
2021
AY4
2022
AY5
2023
FY1
2024
FY2
2025
FY3
2026
FY4
2027
FY5
2028
Revenue 428.4 389.5 413.8 410.6 442.7 447.4 452.1 456.9 461.7 466.5
Revenue Growth, % 0 -9.08 6.22 -0.76302 7.83 1.05 1.05 1.05 1.05 1.05
EBITDA 101.1 141.9 233.3 261.4 -924.9 71.7 72.4 73.2 74.0 74.7
EBITDA, % 23.6 36.43 56.39 63.67 -208.9 16.02 16.02 16.02 16.02 16.02
Depreciation 5.6 3.6 1.5 1.4 1.6 2.9 3.0 3.0 3.0 3.1
Depreciation, % 1.3 0.91497 0.36809 0.34535 0.35574 0.65733 0.65733 0.65733 0.65733 0.65733
EBIT 95.5 138.3 231.8 260.0 -926.4 69.1 69.8 70.5 71.3 72.0
EBIT, % 22.3 35.51 56.03 63.33 -209.25 15.43 15.43 15.43 15.43 15.43
Total Cash 177.0 362.6 620.1 656.2 92.2 317.8 321.2 324.6 328.0 331.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 117.2 122.4 114.0 115.5 129.1
Account Receivables, % 27.37 31.41 27.56 28.12 29.16
Inventories .6 .0 1.3 1.3 .0 .7 .7 .7 .7 .7
Inventories, % 0.15126 0.000000257 0.30211 0.30444 0 0.15156 0.15156 0.15156 0.15156 0.15156
Accounts Payable 5.5 .7 .9 .5 7.8 3.2 3.2 3.3 3.3 3.3
Accounts Payable, % 1.28 0.16969 0.22598 0.11763 1.77 0.71253 0.71253 0.71253 0.71253 0.71253
Capital Expenditure -7.2 -1.8 -.3 -.1 -.3 -2.1 -2.1 -2.1 -2.1 -2.2
Capital Expenditure, % -1.68 -0.47289 -0.06404787 -0.03312258 -0.06166217 -0.46195 -0.46195 -0.46195 -0.46195 -0.46195
Tax Rate, % -5.71 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71
EBITAT -24.8 134.9 610.5 180.3 -979.4 50.7 51.2 51.7 52.3 52.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -138.8 127.4 619.1 179.7 -983.1 46.8 50.8 51.3 51.8 52.4
WACC, % 1.7 4.7 4.77 3.83 4.77 3.95 3.95 3.95 3.95 3.95
PV UFCF
SUM PV UFCF 225.2
Long Term Growth Rate, % 0.50
Free cash flow (T + 1) 53
Terminal Value 1,524
Present Terminal Value 1,256
Enterprise Value 1,481
Net Debt 623
Equity Value 858
Diluted Shares Outstanding, MM 155
Equity Value Per Share 5.52

What You Will Get

  • Real IRWD Financial Data: Pre-filled with Ironwood Pharmaceuticals’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Ironwood Pharmaceuticals’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Customizable Forecast Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and R&D expenditures.
  • Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other key financial indicators.
  • High-Precision Accuracy: Leverages Ironwood's actual financial data for dependable valuation results.
  • Effortless Scenario Analysis: Easily evaluate various assumptions and analyze different outcomes.
  • Efficiency Booster: Streamline your workflow by avoiding the complexity of creating valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Ironwood Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Ironwood Pharmaceuticals’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose Ironwood Pharmaceuticals, Inc. (IRWD)?

  • Innovative Solutions: Cutting-edge therapies tailored to meet patient needs.
  • Proven Track Record: Strong clinical results and a commitment to quality.
  • Patient-Centric Approach: Focused on enhancing the patient experience and outcomes.
  • Expert Team: A dedicated group of professionals driving research and development.
  • Industry Recognition: A trusted name in pharmaceuticals with numerous accolades.

Who Should Use This Product?

  • Investors: Assess the fair value of Ironwood Pharmaceuticals (IRWD) to inform your investment choices.
  • CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis.
  • Consultants: Easily customize the template for client valuation reports.
  • Entrepreneurs: Understand financial modeling techniques employed by leading pharmaceutical companies.
  • Educators: Implement it as a resource to teach valuation methods effectively.

What the Template Contains

  • Historical Data: Includes Ironwood Pharmaceuticals’ past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Ironwood Pharmaceuticals’ intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Ironwood Pharmaceuticals’ financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.